Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957728 | 0.93 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL384423 | 0.93 | NPC1 (0.63) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL531915 | 0.91 | NPC1 (0.66) | RAB9ANPC1SMN1; SMN2KMT2AHPGD | |
| SCHEMBL15299247 | 0.89 | NAMPT (0.51) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL19869658 | 0.86 | SLC6A5 (0.51) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL20850172 | 0.82 | NPC1 (0.58) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL7305442 | 0.81 | NPC1 (0.46) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL148956 | 0.80 | NPC1 (0.56) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1477302 | 0.79 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6569206 | 0.79 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113710668-B | Condensed azines for EP300 or CBP modulation and indications thereof | OPNA生物公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-117285523-A | Apigenin derivative and application thereof in resisting tumors | 中南大学 | 2023-12-26 | — | — | CN | disclosed |
| CN-115160277-B | Apigenin derivative and application thereof | 中南大学 | 2023-11-07 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-115160277-A | Apigenin derivative and application thereof | 中南大学 | 2022-10-11 | — | — | CN | disclosed |
| US-11446287-B2 | Compounds and methods for EP300 or CBP modulation and indications therefor | OPNA IMMUNO-ONCOLOGY SA (CH) | 2022-09-20 | — | — | US | disclosed |
| EP-3953351-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | disclosed |
| CN-113710668-A | Condensed azines for EP300 or CBP modulation and indications therefor | 普莱希科公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-11-08 | — | — | US | disclosed |
| WO-2007124254-A2 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| WO-2007103308-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | RAB9A 2056/4885NPC1 1260/4885SMN1; SMN2 2264/4885 |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, TSLP, IFNG | RAB9A 2928/4885NPC1 1672/4885SMN1; SMN2 4726/4885 |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | IL4, IL2, IL5 | RAB9A 2978/4885NPC1 2438/4885SMN1; SMN2 3137/4885 |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | RAB9A 4102/4885NPC1 2905/4885SMN1; SMN2 709/4885 |
| US-11446287-B2 | Compounds and methods for EP300 or CBP modulation and indications therefor | EP300, CREBBP, HDAC11 | RAB9A 4528/4885NPC1 1461/4885SMN1; SMN2 2533/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | RAB9A 2498/4885NPC1 2180/4885SMN1; SMN2 1840/4885 |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | IL2, IRF3, EIF2AK2 | RAB9A 2097/4885NPC1 2496/4885SMN1; SMN2 3309/4885 |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | EP300, CREBBP, HDAC11 | RAB9A 4529/4885NPC1 1410/4885SMN1; SMN2 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.